Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | PDGFRB rearrange |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PDGFR Inhibitor (Pan) PDGFR-beta Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| PDGFRB rearrange | myelodysplastic/myeloproliferative neoplasm | sensitive | PDGFR Inhibitor (Pan) | Imatinib | FDA approved - On Companion Diagnostic | Actionable | Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFRB rearrangements and detected by a companion diagnostic (FDA.gov). | detail... detail... detail... |
| PDGFRB rearrange | Advanced Solid Tumor | predicted - sensitive | PDGFR Inhibitor (Pan) | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a PDGFRB rearrangement were sensitive to treatment with Gleevec (imatinib), demonstrating decreased colony formation and reduced cell growth in culture (PMID: 31645346). | 31645346 |
| PDGFRB rearrange | myeloid and lymphoid neoplasms associated with PDGFRB rearrangement | sensitive | PDGFR Inhibitor (Pan) | Imatinib | Guideline | Actionable | Gleevec (imatinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a PDGFRB rearrangement (NCCN.org). | detail... |
| PDGFRB rearrange | childhood B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | PDGFRB rearrangements are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... | |
| PDGFRB rearrange | B-cell acute lymphoblastic leukemia | not applicable | N/A | Guideline | Prognostic | PDGFRB rearrangements are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org). | detail... | |
| PDGFRB rearrange | chronic myelomonocytic leukemia | sensitive | PDGFR Inhibitor (Pan) | Imatinib | Guideline | Actionable | Gleevec (imatinib) is included in guidelines for patients with chronic myelomonocytic leukemia harboring a PDGFRB rearrangement (NCCN.org). | detail... |